<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="mutate">
            <roleset id="Mutate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="physical location where mutation happen// exon, intron //&#x0A;" />
                    <role n="1" descr="mutated entity   // gene //&#x0A;" />
                    <role n="2" descr="changes at molecular level/* always use prepositional phrase */&#x0A;" />
                    <role n="3" descr="changes at phenotype level /* secondary predication */  &#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Alpha-chain cDNA in COS-1 cells can be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Alpha-chain cDNA in COS-1 cells can be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Alpha-chain cDNA in COS-1 cells could be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Alpha-chain cDNA in COS-1 cells could be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Alpha-chain cDNA in COS-1 cells could have been mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Alpha-chain cDNA in COS-1 cells could have been significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Alpha-chain cDNA in COS-1 cells has been mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Alpha-chain cDNA in COS-1 cells has been significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Alpha-chain cDNA in COS-1 cells has the ability to be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Alpha-chain cDNA in COS-1 cells has the ability to be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Alpha-chain cDNA in COS-1 cells has the probability of being mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Alpha-chain cDNA in COS-1 cells has the probability of being significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Alpha-chain cDNA in COS-1 cells is able to be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Alpha-chain cDNA in COS-1 cells is able to be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Alpha-chain cDNA in COS-1 cells is mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Alpha-chain cDNA in COS-1 cells is observed to be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Alpha-chain cDNA in COS-1 cells is observed to be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Alpha-chain cDNA in COS-1 cells is significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Alpha-chain cDNA in COS-1 cells may be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Alpha-chain cDNA in COS-1 cells may be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Alpha-chain cDNA in COS-1 cells may have been mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Alpha-chain cDNA in COS-1 cells may have been significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Alpha-chain cDNA in COS-1 cells might be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Alpha-chain cDNA in COS-1 cells might be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Alpha-chain cDNA in COS-1 cells might have been mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Alpha-chain cDNA in COS-1 cells might have been significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Alpha-chain cDNA in COS-1 cells was mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Alpha-chain cDNA in COS-1 cells was significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Alpha-chain cDNA in COS-1 cells will be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Alpha-chain cDNA in COS-1 cells will be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Alpha-chain cDNA in COS-1 cells would be mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Alpha-chain cDNA in COS-1 cells would be significantly mutated by transient expression of the exon 8 resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences being mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences that are able to be mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences that are mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences that can be mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences that have been mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences that may have been mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences that were mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences which are able to be mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences which are mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences which can be mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences which have been mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences which may have been mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Analyses of transcription in vivo of agn-lacZ with Dam target sequences which were mutated support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated Dam target sequences support this conclusion.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with mutated p53, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that can be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that can be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that could be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that could be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that has been mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that has been remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that has the ability to be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that has the ability to be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that is able to be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that is able to be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that is believed to be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that is believed to be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that is mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that is observed to be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that is observed to be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that is remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that may be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that may be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that might be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that might be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that might have been mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that might have been remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that will be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that will be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that would be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 that would be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which can be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which can be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which could be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which could be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which has been mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which has been remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which has the ability to be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which has the ability to be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which is able to be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which is able to be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which is believed to be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which is believed to be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which is mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which is observed to be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which is observed to be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which is remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which might be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which might be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which might have been mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which might have been remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which will be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which will be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which would be mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with p53 which would be remarkably mutated, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>For example, mutating the C-terminal MAP kinase sites (T235 and T239) essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>For example, mutating the C-terminal MAP kinase sites (T235 and T239) has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>For example, mutating the C-terminal MAP kinase sites (T235 and T239) is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>For example, mutating the C-terminal MAP kinase sites (T235 and T239) may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>For example, to mutate the C-terminal MAP kinase sites (T235 and T239) essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>For example, to mutate the C-terminal MAP kinase sites (T235 and T239) has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>For example, to mutate the C-terminal MAP kinase sites (T235 and T239) is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>For example, to mutate the C-terminal MAP kinase sites (T235 and T239) may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) are able to be mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) are able to be significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) are mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) are significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) could have already been mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) could have already been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) could have been mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) could have been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) have already been mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) have already been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) have been mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) have been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) have the ability to be mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) have the ability to be significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) were mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) were observed to be mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) were observed to be significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) were significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>In contrast, to mutate the C-terminal MAP kinase sites (T235 and T239) essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>In contrast, to mutate the C-terminal MAP kinase sites (T235 and T239) has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>In contrast, to mutate the C-terminal MAP kinase sites (T235 and T239) is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>In contrast, to mutate the C-terminal MAP kinase sites (T235 and T239) may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>Induction of a mutation in the lacI gene can result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>Induction of a mutation in the lacI gene could have resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>Induction of a mutation in the lacI gene has resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>Induction of a mutation in the lacI gene has the ability to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>Induction of a mutation in the lacI gene is able to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>Induction of a mutation in the lacI gene is observed to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>Induction of a mutation in the lacI gene may have resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>Induction of a mutation in the lacI gene may result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>Induction of a mutation in the lacI gene resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>Induction of a mutation in the lacI gene results in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>Induction of a mutation in the lacI gene will result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>Induction of a mutation in the lacI gene, for example, can result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>Induction of a mutation in the lacI gene, for example, could have resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>Induction of a mutation in the lacI gene, for example, has resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>Induction of a mutation in the lacI gene, for example, has the ability to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>Induction of a mutation in the lacI gene, for example, is able to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>Induction of a mutation in the lacI gene, for example, is observed to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>Induction of a mutation in the lacI gene, for example, may have resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Induction of a mutation in the lacI gene, for example, may result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Induction of a mutation in the lacI gene, for example, resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Induction of a mutation in the lacI gene, for example, results in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Induction of a mutation in the lacI gene, for example, will result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Induction of a mutation in the lacI gene, in contrast, can result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Induction of a mutation in the lacI gene, in contrast, could have resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Induction of a mutation in the lacI gene, in contrast, has resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Induction of a mutation in the lacI gene, in contrast, has the ability to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Induction of a mutation in the lacI gene, in contrast, is able to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Induction of a mutation in the lacI gene, in contrast, is observed to result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Induction of a mutation in the lacI gene, in contrast, may have resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Induction of a mutation in the lacI gene, in contrast, may result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Induction of a mutation in the lacI gene, in contrast, resulted in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Induction of a mutation in the lacI gene, in contrast, results in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Induction of a mutation in the lacI gene, in contrast, will result in the loss of transcriptional repression of the lacZ gene that is mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Mutating a conserved phenylalanine of the eh1/GEH sequence to glutamic acid abolished groucho binding (Jimnez et al., 1999).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                    <arg n="2">to glutamic acid</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Mutating amino acids EE(437 and 438) to AA can generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Mutating amino acids EE(437 and 438) to AA could generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Mutating amino acids EE(437 and 438) to AA could have generated the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Mutating amino acids EE(437 and 438) to AA generated the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Mutating amino acids EE(437 and 438) to AA generates the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>Mutating amino acids EE(437 and 438) to AA has generated the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>Mutating amino acids EE(437 and 438) to AA has the ability to generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>Mutating amino acids EE(437 and 438) to AA is able to generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>Mutating amino acids EE(437 and 438) to AA is observed to generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>Mutating amino acids EE(437 and 438) to AA may generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>Mutating amino acids EE(437 and 438) to AA may have generated the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>Mutating amino acids EE(437 and 438) to AA might generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>Mutating amino acids EE(437 and 438) to AA will generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>Mutating amino acids EE(437 and 438) to AA would generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>Mutating the C-terminal MAP kinase sites (T235 and T239), for example, essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>Mutating the C-terminal MAP kinase sites (T235 and T239), for example, has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>Mutating the C-terminal MAP kinase sites (T235 and T239), for example, is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>Mutating the C-terminal MAP kinase sites (T235 and T239), for example, may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>Mutating the C-terminal MAP kinase sites (T235 and T239), in contrast, essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>Mutating the C-terminal MAP kinase sites (T235 and T239), in contrast, has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>Mutating the C-terminal MAP kinase sites (T235 and T239), in contrast, is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>Mutating the C-terminal MAP kinase sites (T235 and T239), in contrast, may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>Our research has shown that mutating the C-terminal MAP kinase sites (T235 and T239) essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>Our research has shown that mutating the C-terminal MAP kinase sites (T235 and T239) has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>Our research has shown that mutating the C-terminal MAP kinase sites (T235 and T239) is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>Our research has shown that mutating the C-terminal MAP kinase sites (T235 and T239) may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>Our research has shown that to mutate the C-terminal MAP kinase sites (T235 and T239) essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>Our research has shown that to mutate the C-terminal MAP kinase sites (T235 and T239) has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>Our research has shown that to mutate the C-terminal MAP kinase sites (T235 and T239) is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>Our research has shown that to mutate the C-terminal MAP kinase sites (T235 and T239) may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites are able to be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites are able to be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites are mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites are observed to be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites are observed to be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites are remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites could have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites could have been remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites have been remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites have the ability to be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites have the ability to be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites may have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites may have been remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites might be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites might be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites were mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites were remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites will be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites will be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, are able to be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, are mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, are observed to be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, could have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, have the ability to be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, may have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, might be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, were mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as our study suggested, will be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, are able to be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, are observed to be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, are remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, could have been remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, have been remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, have the ability to be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, may have been remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, might be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, were remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites, as we predicted, will be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions being able to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions being observed to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions mutating in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions observed to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that are able to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that are observed to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that can mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that could have mutated in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that could mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that has mutated in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that have the ability to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that may mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that might have mutated in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that might mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that mutated in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that will mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that would mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which are able to mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which are observed to mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which can mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which could have mutated in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which could mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which has mutated in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which have the ability to mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which may mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which might have mutated in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which might mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which mutated in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which will mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions which would mutate in a coordinated manner, and (ii) using these results to identify protein regions which interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="EGRAM" no="263">
                    <text>The DNA-binding mutant(Stat5aEE-AA) of Stat5a can be generated by mutating amino acids EE(437 and 438) to AA.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="264">
                    <text>The DNA-binding mutant(Stat5aEE-AA) of Stat5a could have been generated by mutating amino acids EE(437 and 438) to AA.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="265">
                    <text>The DNA-binding mutant(Stat5aEE-AA) of Stat5a has been generated by mutating amino acids EE(437 and 438) to AA.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="266">
                    <text>The DNA-binding mutant(Stat5aEE-AA) of Stat5a is generated by mutating amino acids EE(437 and 438) to AA.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="267">
                    <text>The DNA-binding mutant(Stat5aEE-AA) of Stat5a is observed to be generated by mutating amino acids EE(437 and 438) to AA.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="268">
                    <text>The exon 5 being able to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="269">
                    <text>The exon 5 can mutate allele with the premature translation termination and results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="270">
                    <text>The exon 5 could have mutated allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="271">
                    <text>The exon 5 could mutate allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="272">
                    <text>The exon 5 had the ability to mutate allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="273">
                    <text>The exon 5 had the probability of mutating allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="274">
                    <text>The exon 5 has mutated allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="275">
                    <text>The exon 5 having the ability to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="276">
                    <text>The exon 5 is mutating allele with the premature translation termination and results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="277">
                    <text>The exon 5 may mutate allele with the premature translation termination and results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="278">
                    <text>The exon 5 might have mutated allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="279">
                    <text>The exon 5 might mutate allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="280">
                    <text>The exon 5 mutates allele with the premature translation termination and results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="281">
                    <text>The exon 5 mutating allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="282">
                    <text>The exon 5 observed to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="283">
                    <text>The exon 5 that can mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="284">
                    <text>The exon 5 that could have mutated allele with the premature translation termination resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="285">
                    <text>The exon 5 that has the ability to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="286">
                    <text>The exon 5 that have mutated allele with the premature translation termination resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="287">
                    <text>The exon 5 that is able to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="288">
                    <text>The exon 5 that is observed to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="289">
                    <text>The exon 5 that may have mutated allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="290">
                    <text>The exon 5 that may mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="291">
                    <text>The exon 5 that mutated allele with the premature translation termination resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="292">
                    <text>The exon 5 that mutates allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="293">
                    <text>The exon 5 that will mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="294">
                    <text>The exon 5 was able to mutate allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="295">
                    <text>The exon 5 was observed to mutate allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="296">
                    <text>The exon 5 which can mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="297">
                    <text>The exon 5 which could have mutated allele with the premature translation termination resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="298">
                    <text>The exon 5 which has the ability to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="299">
                    <text>The exon 5 which have mutated allele with the premature translation termination resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="300">
                    <text>The exon 5 which is able to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="301">
                    <text>The exon 5 which is observed to mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="302">
                    <text>The exon 5 which may have mutated allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="303">
                    <text>The exon 5 which may mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="304">
                    <text>The exon 5 which mutated allele with the premature translation termination resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="305">
                    <text>The exon 5 which mutates allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="306">
                    <text>The exon 5 which will mutate allele with the premature translation termination results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="307">
                    <text>The exon 5 will mutate allele with the premature translation termination and results in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="308">
                    <text>The exon 5 would mutate allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="EGRAM" no="309">
                    <text>The gene being able to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="310">
                    <text>The gene being able to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="311">
                    <text>The gene being mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="312">
                    <text>The gene being mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="313">
                    <text>The gene having the ability to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="314">
                    <text>The gene having the ability to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="315">
                    <text>The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="316">
                    <text>The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="317">
                    <text>The gene observed to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="318">
                    <text>The gene observed to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="319">
                    <text>The gene that can be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="320">
                    <text>The gene that can be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="321">
                    <text>The gene that has been mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="322">
                    <text>The gene that has been mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="323">
                    <text>The gene that has the ability to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="324">
                    <text>The gene that has the ability to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="325">
                    <text>The gene that is able to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="326">
                    <text>The gene that is able to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="327">
                    <text>The gene that is mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="328">
                    <text>The gene that is mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="329">
                    <text>The gene that is observed to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="330">
                    <text>The gene that is observed to be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="331">
                    <text>The gene that may be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="332">
                    <text>The gene that may be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="333">
                    <text>The gene that may have been mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="334">
                    <text>The gene that may have been mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="335">
                    <text>The gene that was mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="336">
                    <text>The gene that was mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="337">
                    <text>The gene that will be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="338">
                    <text>The gene that will be mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice has encoded a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="339">
                    <text>The result of mutating amino acids EE(437 and 438) to AA is the DNA-binding mutant(Stat5aEE-AA) of Stat5a being generated.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="340">
                    <text>The template fragments are able to be mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="341">
                    <text>The template fragments are able to be significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="342">
                    <text>The template fragments are mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="343">
                    <text>The template fragments are observed to be mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="344">
                    <text>The template fragments are observed to be significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="345">
                    <text>The template fragments are significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="346">
                    <text>The template fragments can be mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="347">
                    <text>The template fragments can be significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="348">
                    <text>The template fragments could be mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="349">
                    <text>The template fragments could be significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="350">
                    <text>The template fragments could have been mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="351">
                    <text>The template fragments could have been significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="352">
                    <text>The template fragments have been mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="353">
                    <text>The template fragments have been significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="354">
                    <text>The template fragments have the probability of being mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="355">
                    <text>The template fragments have the probability of being significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="356">
                    <text>The template fragments may be mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="357">
                    <text>The template fragments may be significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="358">
                    <text>The template fragments might be mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="359">
                    <text>The template fragments might be significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="360">
                    <text>The template fragments might have been mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="361">
                    <text>The template fragments might have been significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="362">
                    <text>The template fragments will be mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="363">
                    <text>The template fragments will be significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="364">
                    <text>The template fragments would be mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="365">
                    <text>The template fragments would be significantly mutated by the sequence of SAP97 RAT, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="366">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids being able to commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="367">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids being able to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="368">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids commonly mutating (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="369">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids mutating (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="370">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids observed to commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="371">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids observed to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="372">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that are able to commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="373">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that are able to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="374">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that are commonly mutating (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="375">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that are mutating (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="376">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that are observed to commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="377">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that are observed to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="378">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that can commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="379">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that can mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="380">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that could have commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="381">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that could have mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="382">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that have commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="383">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that have mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="384">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that may commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="385">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that may have commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="386">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that may have mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="387">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that may mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="388">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="389">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that will commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="390">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that will mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="391">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which are able to commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="392">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which are able to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="393">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which are commonly mutating (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="394">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which are mutating (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="395">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which are observed to commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="396">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which are observed to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="397">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which can commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="398">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which can mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="399">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which could have commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="400">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which could have mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="401">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which have commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="402">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which have mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="403">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which may commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="404">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which may have commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="405">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which may have mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="406">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which may mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="407">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="408">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which will commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="409">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids which will mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="410">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, the activator-interaction domains in the complex have been identified and mutated.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="411">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, the activator-interaction domains in the complex were identified and mutated.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="412">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, the activator-interaction domains in the complex will be identified and mutated.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="413">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we found to identify and mutate the activator-interaction domains in the complex.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="414">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we have identified and mutated the activator-interaction domains in the complex.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="415">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identified and mutated the activator-interaction domains in the complex.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="416">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identify and mutate the activator-interaction domains in the complex.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="417">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we will identify and mutate the activator-interaction domains in the complex.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="418">
                    <text>To mutate a conserved phenylalanine of the eh1/GEH sequence to glutamic acid abolished groucho binding (Jimnez et al., 1999).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                    <arg n="2">to glutamic acid</arg>
                </example>
                <example src="EGRAM" no="419">
                    <text>To mutate amino acids EE(437 and 438) to AA can generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="420">
                    <text>To mutate amino acids EE(437 and 438) to AA could generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="421">
                    <text>To mutate amino acids EE(437 and 438) to AA could have generated the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="422">
                    <text>To mutate amino acids EE(437 and 438) to AA generated the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="423">
                    <text>To mutate amino acids EE(437 and 438) to AA generates the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="424">
                    <text>To mutate amino acids EE(437 and 438) to AA has generated the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="425">
                    <text>To mutate amino acids EE(437 and 438) to AA has the ability to generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="426">
                    <text>To mutate amino acids EE(437 and 438) to AA is able to generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="427">
                    <text>To mutate amino acids EE(437 and 438) to AA is observed to generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="428">
                    <text>To mutate amino acids EE(437 and 438) to AA may generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="429">
                    <text>To mutate amino acids EE(437 and 438) to AA may have generated the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="430">
                    <text>To mutate amino acids EE(437 and 438) to AA might generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="431">
                    <text>To mutate amino acids EE(437 and 438) to AA will generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="432">
                    <text>To mutate amino acids EE(437 and 438) to AA would generate the DNA-binding mutant(Stat5aEE-AA) of Stat5a.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EGRAM" no="433">
                    <text>To mutate the C-terminal MAP kinase sites (T235 and T239), for example, essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="434">
                    <text>To mutate the C-terminal MAP kinase sites (T235 and T239), for example, has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="435">
                    <text>To mutate the C-terminal MAP kinase sites (T235 and T239), for example, is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="436">
                    <text>To mutate the C-terminal MAP kinase sites (T235 and T239), for example, may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="437">
                    <text>To mutate the C-terminal MAP kinase sites (T235 and T239), in contrast, essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="438">
                    <text>To mutate the C-terminal MAP kinase sites (T235 and T239), in contrast, has essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="439">
                    <text>To mutate the C-terminal MAP kinase sites (T235 and T239), in contrast, is observed to essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="440">
                    <text>To mutate the C-terminal MAP kinase sites (T235 and T239), in contrast, may have essentially led to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EGRAM" no="441">
                    <text>Transient expression of the exon 8 can mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="442">
                    <text>Transient expression of the exon 8 can significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="443">
                    <text>Transient expression of the exon 8 could have mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="444">
                    <text>Transient expression of the exon 8 could have significantly mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="445">
                    <text>Transient expression of the exon 8 could mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="446">
                    <text>Transient expression of the exon 8 could significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="447">
                    <text>Transient expression of the exon 8 has mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="448">
                    <text>Transient expression of the exon 8 has significantly mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="449">
                    <text>Transient expression of the exon 8 has the ability to mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="450">
                    <text>Transient expression of the exon 8 has the ability to significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="451">
                    <text>Transient expression of the exon 8 is able to mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="452">
                    <text>Transient expression of the exon 8 is able to significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="453">
                    <text>Transient expression of the exon 8 is believe to mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="454">
                    <text>Transient expression of the exon 8 is believe to significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="455">
                    <text>Transient expression of the exon 8 is observed to mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="456">
                    <text>Transient expression of the exon 8 is observed to significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="457">
                    <text>Transient expression of the exon 8 may have mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="458">
                    <text>Transient expression of the exon 8 may have significantly mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="459">
                    <text>Transient expression of the exon 8 may mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="460">
                    <text>Transient expression of the exon 8 may significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="461">
                    <text>Transient expression of the exon 8 might have mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="462">
                    <text>Transient expression of the exon 8 might have significantly mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="463">
                    <text>Transient expression of the exon 8 might mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="464">
                    <text>Transient expression of the exon 8 might significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="465">
                    <text>Transient expression of the exon 8 mutates alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="466">
                    <text>Transient expression of the exon 8 significantly mutates alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="467">
                    <text>Transient expression of the exon 8 will mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="468">
                    <text>Transient expression of the exon 8 will significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="469">
                    <text>Transient expression of the exon 8 would mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="470">
                    <text>Transient expression of the exon 8 would significantly mutate alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="EGRAM" no="471">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being completely mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EGRAM" no="472">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EGRAM" no="473">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being significantly mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EGRAM" no="474">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when completely mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EGRAM" no="475">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been completely mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EGRAM" no="476">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EGRAM" no="477">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been significantly mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EGRAM" no="478">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EGRAM" no="479">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when significantly mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>Groucho binding was, however, abolished by mutating a conserved phenylalanine of the eh1/GEH sequence to glutamic acid (Jimnez et al., 1999).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                    <arg n="2">glutamic acid</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>In contrast, mutating the C-terminal MAP kinase sites (T235 and T239) essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EMBO" no="4">
                    <text>The DNA-binding mutant(Stat5aEE-AA) of Stat5a was generated by mutating amino acids EE(437 and 438) to AA.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EMBO" no="5">
                    <text>The template fragments were mutated by the sequence of SAP97 RAT, accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="GREC" no="1">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated Dam target sequences support this conclusion.</text>
                    <arg n="0">Dam target sequences</arg>
                </example>
                <example src="GREC" no="2">
                    <text>Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with mutated p53, and a 4-fold repression with wild-type p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="3">a 7-fold induction</arg>
                </example>
                <example src="GREC" no="3">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (S (64) and S (211)) were mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="GREC" no="4">
                    <text>Induction of a mutation in the lacI gene will result in the loss of transcriptional repression of the lacZ gene in mutated cells.</text>
                    <arg n="0">LacI</arg>
                    <arg n="3">the loss of transcriptional repression of the lacZ gene in mutated cells</arg>
                </example>
                <example src="GREC" no="5">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>The exon 5 mutated allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="MEDLINE" no="3">
                    <text>The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="MEDLINE" no="4">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="MEDLINE" no="5">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we sought to identify and mutate the activator-interaction domains in the complex.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="MEDLINE" no="6">
                    <text>Transient expression of the exon 8 mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>ALK4 extracellular domain are able to be mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>ALK4 extracellular domain are able to be mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>ALK4 extracellular domain are able to be significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>ALK4 extracellular domain are able to be significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>ALK4 extracellular domain are mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>ALK4 extracellular domain are mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>ALK4 extracellular domain are observed to be mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>ALK4 extracellular domain are observed to be mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>ALK4 extracellular domain are observed to be significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>ALK4 extracellular domain are observed to be significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>ALK4 extracellular domain are significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>ALK4 extracellular domain are significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>ALK4 extracellular domain can be mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>ALK4 extracellular domain can be mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>ALK4 extracellular domain can be significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>ALK4 extracellular domain can be significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>ALK4 extracellular domain could be mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>ALK4 extracellular domain could be mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>ALK4 extracellular domain could be significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>ALK4 extracellular domain could be significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>ALK4 extracellular domain could have been mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>ALK4 extracellular domain could have been mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>ALK4 extracellular domain could have been significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>ALK4 extracellular domain could have been significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>ALK4 extracellular domain have been mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>ALK4 extracellular domain have been mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>ALK4 extracellular domain have been significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>ALK4 extracellular domain have been significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>ALK4 extracellular domain have the probability of being mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>ALK4 extracellular domain have the probability of being mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>ALK4 extracellular domain have the probability of being significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>ALK4 extracellular domain have the probability of being significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>ALK4 extracellular domain may be mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>ALK4 extracellular domain may be mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>ALK4 extracellular domain may be significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>ALK4 extracellular domain may be significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>ALK4 extracellular domain might be mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>ALK4 extracellular domain might be mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>ALK4 extracellular domain might be significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>ALK4 extracellular domain might be significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>ALK4 extracellular domain might have been mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>ALK4 extracellular domain might have been mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>ALK4 extracellular domain might have been significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>ALK4 extracellular domain might have been significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>ALK4 extracellular domain were mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>ALK4 extracellular domain were mutated by five hydrophobic amino acid residues, accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>ALK4 extracellular domain will be mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>ALK4 extracellular domain will be mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>ALK4 extracellular domain will be significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>ALK4 extracellular domain will be significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>ALK4 extracellular domain would be mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>ALK4 extracellular domain would be mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>ALK4 extracellular domain would be significantly mutated by Leu40, Ile70, Val73, Leu75, and Pro77, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>ALK4 extracellular domain would be significantly mutated by five hydrophobic amino acid residues, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) being mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) that are able to be mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) that are mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) that can be mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) that have been mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) that may have been mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) that were mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) which are able to be mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) which are mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) which can be mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) which have been mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) which may have been mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Analyses of transcription in vivo of agn-lacZ with amino acids EE(437 and 438) which were mutated support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated ALK4 extracellular domain support this conclusion.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated SOX9 protein support this conclusion.</text>
                    <arg n="0">SOX9 protein</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated The template fragments support this conclusion.</text>
                    <arg n="0">The template fragments</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated a conserved phenylalanine support this conclusion.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated amino acids EE(437 and 438) support this conclusion.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated the activator-interaction domains in the complex support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated two amino acids support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex being mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex that are able to be mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex that are mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex that can be mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex that have been mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex that may have been mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex that were mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex which are able to be mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex which are mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex which can be mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex which have been mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex which may have been mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Analyses of transcription in vivo of agn-lacZ with the activator-interaction domains in the complex which were mutated support this conclusion.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids being mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids that are able to be mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids that are mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids that can be mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids that have been mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids that may have been mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids that were mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids which are able to be mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids which are mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids which can be mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids which have been mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids which may have been mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Analyses of transcription in vivo of agn-lacZ with two amino acids which were mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 are able to be mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 are able to be significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 are mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 are significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 could have already been mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 could have already been significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 could have been mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 could have been significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 have already been mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 have already been significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 have been mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 have been significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 have the ability to be mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 have the ability to be significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 were mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 were observed to be mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 were observed to be significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which Leu40, Ile70, Val73, Leu75, and Pro77 were significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues are able to be mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues are able to be significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues are mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues are significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues could have already been mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues could have already been significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues could have been mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues could have been significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues have already been mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues have already been significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues have been mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues have been significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues have the ability to be mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues have the ability to be significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues were mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues were observed to be mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues were observed to be significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which five hydrophobic amino acid residues were significantly mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which the two PKA phosphorylation sites (Leu40, Ile70, Val73, Leu75, and Pro77) were mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a ALK4 extracellular domain in which the two PKA phosphorylation sites (five hydrophobic amino acid residues) were mutated.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) are able to be mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) are able to be significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) are mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) are significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) could have already been mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) could have already been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) could have been mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) could have been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) have already been mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) have already been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) have been mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) have been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) have the ability to be mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) have the ability to be significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) were observed to be mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) were observed to be significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which S (64) and S (211) were significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a SOX9 protein in which the two PKA phosphorylation sites (the two PKA phosphorylation sites (S (64) and S (211))) were mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT are able to be mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT are able to be significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT are mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT are significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT could have already been mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT could have already been significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT could have been mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT could have been significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT have already been mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT have already been significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT have been mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT have been significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT have the ability to be mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT have the ability to be significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT were mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT were observed to be mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT were observed to be significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the sequence of SAP97 RAT were significantly mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a The template fragments in which the two PKA phosphorylation sites (the sequence of SAP97 RAT) were mutated.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence are able to be mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence are able to be significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence are mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence are significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence could have already been mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence could have already been significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence could have been mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence could have been significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence have already been mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence have already been significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence have been mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence have been significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence have the ability to be mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence have the ability to be significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence were mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence were observed to be mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence were observed to be significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the eh1/GEH sequence were significantly mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a a conserved phenylalanine in which the two PKA phosphorylation sites (the eh1/GEH sequence) were mutated.</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>Mutating ALK4 extracellular domain of Leu40, Ile70, Val73, Leu75, and Pro77 alanine abolished groucho binding (Jimnez et al., 1999).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>Mutating ALK4 extracellular domain of five hydrophobic amino acid residues alanine abolished groucho binding (Jimnez et al., 1999).</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>SOX9 protein are able to be mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>SOX9 protein are able to be mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>SOX9 protein are able to be significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>SOX9 protein are able to be significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>SOX9 protein are mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>SOX9 protein are mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>SOX9 protein are observed to be mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>SOX9 protein are observed to be mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>SOX9 protein are observed to be significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>SOX9 protein are observed to be significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>SOX9 protein are significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>SOX9 protein are significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>SOX9 protein can be mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>SOX9 protein can be mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>SOX9 protein can be significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>SOX9 protein can be significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>SOX9 protein could be mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>SOX9 protein could be mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>SOX9 protein could be significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>SOX9 protein could be significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>SOX9 protein could have been mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>SOX9 protein could have been mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>SOX9 protein could have been significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>SOX9 protein could have been significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>SOX9 protein have been mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>SOX9 protein have been mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>SOX9 protein have been significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>SOX9 protein have been significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>SOX9 protein have the probability of being mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>SOX9 protein have the probability of being mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>SOX9 protein have the probability of being significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>SOX9 protein have the probability of being significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>SOX9 protein may be mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>SOX9 protein may be mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>SOX9 protein may be significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>SOX9 protein may be significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>SOX9 protein might be mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>SOX9 protein might be mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>SOX9 protein might be significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>SOX9 protein might be significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>SOX9 protein might have been mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>SOX9 protein might have been mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>SOX9 protein might have been significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>SOX9 protein might have been significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>SOX9 protein were mutated by S (64) and S (211), accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>SOX9 protein were mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>SOX9 protein will be mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>SOX9 protein will be mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>SOX9 protein will be significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>SOX9 protein will be significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>SOX9 protein would be mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>SOX9 protein would be mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>SOX9 protein would be significantly mutated by S (64) and S (211), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">S (64) and S (211)</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>SOX9 protein would be significantly mutated by the two PKA phosphorylation sites (S (64) and S (211)), accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9 protein</arg>
                    <arg n="1">the two PKA phosphorylation sites (S (64) and S (211))</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, Dam target sequences have been identified and mutated.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, Dam target sequences were identified and mutated.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, Dam target sequences will be identified and mutated.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, amino acids EE(437 and 438) have been identified and mutated.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, amino acids EE(437 and 438) were identified and mutated.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, amino acids EE(437 and 438) will be identified and mutated.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, two amino acids have been identified and mutated.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, two amino acids were identified and mutated.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, two amino acids will be identified and mutated.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we found to identify and mutate Dam target sequences.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we found to identify and mutate amino acids EE(437 and 438).</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we found to identify and mutate two amino acids.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we have identified and mutated Dam target sequences.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we have identified and mutated amino acids EE(437 and 438).</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we have identified and mutated two amino acids.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identified and mutated Dam target sequences.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identified and mutated amino acids EE(437 and 438).</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identified and mutated two amino acids.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identify and mutate Dam target sequences.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identify and mutate amino acids EE(437 and 438).</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identify and mutate two amino acids.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we sought to identify and mutate Dam target sequences.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we sought to identify and mutate amino acids EE(437 and 438).</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we sought to identify and mutate two amino acids.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we will identify and mutate Dam target sequences.</text>
                    <arg n="1">Dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we will identify and mutate amino acids EE(437 and 438).</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we will identify and mutate two amino acids.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>We have identified Leu40, Ile70, Val73, Leu75, and Pro77 on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being completely mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>We have identified Leu40, Ile70, Val73, Leu75, and Pro77 on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>We have identified Leu40, Ile70, Val73, Leu75, and Pro77 on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being significantly mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>We have identified Leu40, Ile70, Val73, Leu75, and Pro77 on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when completely mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>We have identified Leu40, Ile70, Val73, Leu75, and Pro77 on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been completely mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>We have identified Leu40, Ile70, Val73, Leu75, and Pro77 on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>We have identified Leu40, Ile70, Val73, Leu75, and Pro77 on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been significantly mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>We have identified Leu40, Ile70, Val73, Leu75, and Pro77 on the ALK4 extracellular domain (Leu40, Ile70, Val73, Leu75, and Pro77) that, when significantly mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">Leu40, Ile70, Val73, Leu75, and Pro77</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (five hydrophobic amino acid residues) that, when mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity.</text>
                    <arg n="0">ALK4 extracellular domain</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">have substantial effects on ALK4-trunc dominant negative activity</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>a conserved phenylalanine are able to be mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>a conserved phenylalanine are able to be significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>a conserved phenylalanine are mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>a conserved phenylalanine are observed to be mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>a conserved phenylalanine are observed to be significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>a conserved phenylalanine are significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>a conserved phenylalanine can be mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>a conserved phenylalanine can be significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>a conserved phenylalanine could be mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>a conserved phenylalanine could be significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>a conserved phenylalanine could have been mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>a conserved phenylalanine could have been significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>a conserved phenylalanine have been mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>a conserved phenylalanine have been significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>a conserved phenylalanine have the probability of being mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>a conserved phenylalanine have the probability of being significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>a conserved phenylalanine may be mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>a conserved phenylalanine may be significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>a conserved phenylalanine might be mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>a conserved phenylalanine might be significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>a conserved phenylalanine might have been mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>a conserved phenylalanine might have been significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>a conserved phenylalanine were mutated by the eh1/GEH sequence, accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>a conserved phenylalanine will be mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>a conserved phenylalanine will be significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>a conserved phenylalanine would be mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>a conserved phenylalanine would be significantly mutated by the eh1/GEH sequence, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene being mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene that are able to be mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene that are mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene that can be mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene that have been mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene that may have been mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene that were mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene which are able to be mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene which are mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene which can be mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene which have been mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene which may have been mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Analyses of transcription in vivo of agn-lacZ with gene which were mutated support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated LacI support this conclusion.</text>
                    <arg n="0">LacI</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated exon 5 support this conclusion.</text>
                    <arg n="0">exon 5</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated exon 8 support this conclusion.</text>
                    <arg n="0">exon 8</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated four of the sites support this conclusion.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated gene support this conclusion.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated p53 support this conclusion.</text>
                    <arg n="0">p53</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated pairs of residue positions support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Analyses of transcription in vivo of agn-lacZ with mutated the C-terminal MAP kinase sites (T235 and T239) support this conclusion.</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions being mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions that are able to be mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions that are mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions that can be mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions that have been mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions that may have been mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions that were mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions which are able to be mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions which are mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions which can be mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions which have been mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions which may have been mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Analyses of transcription in vivo of agn-lacZ with pairs of residue positions which were mutated support this conclusion.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele are able to be mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele are able to be significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele are mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele are significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele could have already been mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele could have already been significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele could have been mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele could have been significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele have already been mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele have already been significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele have been mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele have been significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele have the ability to be mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele have the ability to be significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele were mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele were observed to be mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele were observed to be significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which allele were significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 5 in which the two PKA phosphorylation sites (allele) were mutated.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells are able to be mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells are able to be significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells are mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells are significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells could have already been mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells could have already been significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells could have been mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells could have been significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells have already been mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells have already been significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells have been mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells have been significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells have the ability to be mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells have the ability to be significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells were mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells were observed to be mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells were observed to be significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which alpha-chain cDNA in COS-1 cells were significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>In COS-7 cells cotransfected with PKA-Calpha and SOX9 expression plasmids, PKA enhanced the phosphorylation of wild-type SOX9 but did not affect phosphorylation of a exon 8 in which the two PKA phosphorylation sites (alpha-chain cDNA in COS-1 cells) were mutated.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>Mutating exon 5 of allele the premature translation termination abolished groucho binding (Jimnez et al., 1999).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, gene have been identified and mutated.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, gene were identified and mutated.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, gene will be identified and mutated.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, pairs of residue positions have been identified and mutated.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, pairs of residue positions were identified and mutated.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, pairs of residue positions will be identified and mutated.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we found to identify and mutate gene.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we found to identify and mutate pairs of residue positions.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we have identified and mutated gene.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we have identified and mutated pairs of residue positions.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identified and mutated gene.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identified and mutated pairs of residue positions.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identify and mutate gene.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we identify and mutate pairs of residue positions.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we sought to identify and mutate gene.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we sought to identify and mutate pairs of residue positions.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we will identify and mutate gene.</text>
                    <arg n="1">gene</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we will identify and mutate pairs of residue positions.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>We have identified allele on the exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being completely mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>We have identified allele on the exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>We have identified allele on the exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) that, when being significantly mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>We have identified allele on the exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) that, when completely mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>We have identified allele on the exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been completely mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>We have identified allele on the exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>We have identified allele on the exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) that, when having been significantly mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>We have identified allele on the exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) that, when significantly mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>We have identified allele on the exon 5 (five hydrophobic amino acid residues) that, when mutated to the premature translation termination, severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>exon 5 are able to be mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>exon 5 are able to be significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>exon 5 are mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>exon 5 are observed to be mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>exon 5 are observed to be significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>exon 5 are significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>exon 5 can be mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>exon 5 can be significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>exon 5 could be mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>exon 5 could be significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>exon 5 could have been mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>exon 5 could have been significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>exon 5 have been mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>exon 5 have been significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>exon 5 have the probability of being mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>exon 5 have the probability of being significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>exon 5 may be mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>exon 5 may be significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>exon 5 might be mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>exon 5 might be significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>exon 5 might have been mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>exon 5 might have been significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>exon 5 were mutated by allele, accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>exon 5 will be mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>exon 5 will be significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>exon 5 would be mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>exon 5 would be significantly mutated by allele, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>exon 8 are able to be mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>exon 8 are able to be significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>exon 8 are mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>exon 8 are observed to be mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>exon 8 are observed to be significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>exon 8 are significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>exon 8 can be mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>exon 8 can be significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>exon 8 could be mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>exon 8 could be significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>exon 8 could have been mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>exon 8 could have been significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>exon 8 have been mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>exon 8 have been significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>exon 8 have the probability of being mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>exon 8 have the probability of being significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>exon 8 may be mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>exon 8 may be significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>exon 8 might be mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>exon 8 might be significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>exon 8 might have been mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>exon 8 might have been significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>exon 8 were mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>exon 8 will be mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>exon 8 will be significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>exon 8 would be mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>exon 8 would be significantly mutated by alpha-chain cDNA in COS-1 cells, accession No.Q62696 using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
